News from wuxi biologics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 24, 2021, 19:00 ET WuXi Biologics Wins 2021 CMO Leadership Awards in All Six Core Categories

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the company has ...

Feb 08, 2021, 19:00 ET The World's Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that its MFG5 Drug...

Dec 28, 2020, 04:44 ET WuXi Biologics Receives GMP Certification from Brazil's ANVISA

WuXi Biologics (WuXi Bio) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has received...

Dec 21, 2020, 07:40 ET WuXi Biologics to Acquire Drug Substance Facility in Wuppertal, Germany from Bayer

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and Bayer, today announced an...

Dec 02, 2020, 06:00 ET Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation

Tubulis, WuXi STA and WuXi Biologics today announced a strategic collaboration to manufacture and advance Tubulis' next generation antibody-drug...

Nov 20, 2020, 03:30 ET WuXi Biologics Launched Biologics Integrated Innovation Center in Hangzhou

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced its biologics...

Oct 29, 2020, 05:00 ET WuXi Biologics and AB2 Bio Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and AB2 Bio Ltd., a Swiss advanced...

Aug 17, 2020, 11:32 ET WuXi Biologics Records Excellent Interim Results

Revenue Up 21.0% Y-o-Y to RMB1,944.1 Million Net Profit Up 62.6% to RMB730.7 Million Profit Attributable to Owners of the Company Up 63.6% Y-o-Y to...

Aug 06, 2020, 05:00 ET WuXi Vaccines Appoints Mr. Jian Dong as Chief Executive Officer

WuXi Vaccines, a global leading company with world-class vaccine contract development and manufacturing organization (CDMO) capabilities, is pleased...

Aug 04, 2020, 05:00 ET WuXi Biologics Awarded as "Most Honored Company" by Institutional Investor

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it was awarded as...

Jun 19, 2020, 05:52 ET Embrace Change to Turn Challenges into Opportunities: WuXi Biologics Successfully Hosted the 2nd Investor Day

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that its 2nd Investor Day...

Jun 15, 2020, 20:00 ET WuXi Biologics (Suzhou) Received EMA GMP Certificate for Biosafety Testing

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that its facility in...

Jun 08, 2020, 20:00 ET WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has signed a...

May 27, 2020, 20:00 ET WuXi Biologics Sweeps 2020 CMO Leadership Awards in All Six Categories

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has been...

May 18, 2020, 20:00 ET WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in the United States

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and the Worcester Business...

Apr 30, 2020, 07:00 ET WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and Aravive, Inc. (NASDAQ:ARAV), a...

Apr 27, 2020, 20:00 ET WuXi Biologics Successfully Completes PFS Filling at its Robotic Aseptic Filling Facility

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that its robotic aseptic...

Apr 21, 2020, 20:00 ET WuXi Biologics Completed Acquisition of a Drug Product Manufacturing Facility in Germany

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed the...

Apr 13, 2020, 20:00 ET WuXi Biologics (Suzhou) Successfully Passed First EMA GMP Inspection

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platform, announced that WuXi Biologics...

Mar 26, 2020, 09:32 ET WuXi Biologics Achieved Remarkable Results in 2019

57.2% Revenue Growth to RMB3,983.7 Million 63.0% Gross Profit Growth to RMB1,658.8 Million Adjusted Net Profit Up 60.3% to RMB1,205.0 Million Diluted ...

Mar 10, 2020, 20:00 ET WuXi Biologics Completes Weather-Tight Seal of its Biologics Manufacturing Facility in Ireland

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...

Feb 25, 2020, 08:30 ET WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...

Feb 23, 2020, 19:00 ET WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...

Feb 18, 2020, 05:42 ET WuXi Biologics' Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...

Feb 18, 2020, 05:11 ET WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader

WuXi Vaccines, a new vaccine Contract Development and Manufacturing Organization (CDMO) established between WuXi Biologics (stock code: 2269.HK) and...